Pharmacological efficacy and safety profile of taranabant in preclinical species

Drug Development Research

Volumn 70, Issue 5, 2009, Pages 349-362

  Fong, Tung M ^a   Shearman, L P ^a   Stribling, D S ^a   Shu, J ^a   Lao, J ^a   Huang, C R R ^a   Xiao, J C ^a   Shen, C P ^a   Tyszkiewicz, J ^a   Strack, A M ^a   DeMaula, C ^a   Hubert, M F ^b   Galijatovic Idrizbegovic, A ^a   Owen, R ^b   Huber, A C ^a   Lanning, C L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Dohme Chibret Centre de Recherche Riom   (France)

Author keywords

Cannabinoid receptor; CB1; Rimonabant; Taranabant

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ADENOSINE A3 RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; CALCIUM CHANNEL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; DEXFENFLURAMINE; KAPPA OPIATE RECEPTOR; MELATONIN RECEPTOR; MU OPIATE RECEPTOR; NEUROKININ 2 RECEPTOR; POTASSIUM CHANNEL HERG; RIMONABANT; SEROTONIN 6 RECEPTOR; SODIUM CHANNEL; TARANABANT; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONKEY; MORTALITY; MOUSE; NONHUMAN; OBESITY; PERIPHERAL NERVOUS SYSTEM; RAT; RECEPTOR AFFINITY; REPEATED DRUG DOSE; RODENT; SEIZURE;

EID: 67650651258     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20311     Document Type: Article

References (38)

1. Addy C, Rothenberg P, Li S, Majumdar A, Agrawal N, Li H, Zhong L, Yuan J, Maes A, Dunbar S, et al. 2008a. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol 48:734-744. (Pubitemid 351713158)
2. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser B, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A, et al. 2008b. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78.
3. Auclair N, Otani S, Soubrie P, Crepel F. 2000. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 83:3287-3293. (Pubitemid 30408863)
4. Beardsley PM, Scimeca JA, Martin BR. 1987. Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 241:521-526. (Pubitemid 17111557)
5. BouaboulaM, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. 1997. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339. (Pubitemid 27382869)
6. Burns HD, Van Laere K, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng WS, Gibson R, Ryan C, Connolly B, Patel S, et al. 2007. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 104:9800-9805. (Pubitemid 47175347)
7. Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, Makriyannis A, Sharkey KA. 2007. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293:R2185-R2193. (Pubitemid 350224010)
8. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. 1998. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 63:113-117. (Pubitemid 28378339)
9. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, et al. 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431. (Pubitemid 38063771)
10. Despres JP, Golay A, Sjostrom L. 2005. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134. (Pubitemid 41653104)
11. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, et al. 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825. (Pubitemid 32303781)
12. EMEA. 2006. European Public Assessment Report of the European Medicines Agency, Scientific Discussion-Accomplia (Rimonabant). http://www.emea.europa.eu/ humandocs/Humans/EPAR/ acomplia/acomplia.htm.
13. FDA. 2007. Transcript, Endocrinologic and Metabolic Drugs Advisory Committee Meeting of the US FDA, June 13, 2007. http://www.fda.gov/ohrms/ dockets/ac/cder07.htm]EndocrinologicMetabolic.
14. Fong TM, Guan X-M, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, et al. 2007. Anti-obesity efficacy of a novel cannabinoid-1 receptor inverse agonist MK-0364 in rodents. J Pharmacol Exp Ther 321:1013-1022.
15. Fong TM, Van der Ploeg LH. 2000. A melanocortin agonist reduces neuronal firing rate in rat hypothalamic slices. Neurosci Lett 283:5-8. (Pubitemid 30145483)
16. Gresl TA, Colman RJ, Havighurst TC, Byerley LO, Allison DB, Schoeller DA, Kemnitz JW. 2003. Insulin sensitivity and glucose effectiveness from three minimal models: effects of energy restriction and body fat in adult male rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 285:R1340-R1354. (Pubitemid 37464393)
17. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC. 1990. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
18. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
19. Jamshidi N, Taylor DA. 2001. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134:1151-1154. (Pubitemid 33097243)
20. Kirkham TC, Williams CM, Fezza F, Di Marzo V. 2002. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550-557. (Pubitemid 34717699)
21. Lange JH, Coolen HK, van Stuivenberg HH, Dijksman JA, Herremans AH, Ronken E, Keizer HG, Tipker K, McCreary AC, Veerman W, et al. 2004. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem 47:627-643. (Pubitemid 38129720)
22. Lin LS, Lanza TJ, Jr., Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, et al. 2006. Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3- cyanophenyl)-1-methylpropyl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl] oxypropanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 49:7584-7587. (Pubitemid 46033647)
23. MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW. 1998. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 124:619-622. (Pubitemid 28276796)
24. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL. 2004. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24:53-62. (Pubitemid 38181669)
25. Mundt S, Solly K, Thieringer R, Hermanowski-Vosatka A. 2005. Development and application of a scintillation proximity assay (SPA) for identification of selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Assay Drug Dev Technol 3:367-375. (Pubitemid 41489392)
26. Pertwee RG. 2005. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
27. Priest BT, Garcia ML, Middleton RE, Brochu RM, Clark S, Dai G, Dick IE, Felix JP, Liu CJ, Reiseter BS, et al. 2004. A disubstituted succinamide is a potent sodium channel blocker with efficacy in a rat pain model. Biochemistry 43:9866-9876. (Pubitemid 38993836)
28. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P. 2003. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345-R353. (Pubitemid 36120150)
29. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, et al. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244. (Pubitemid 24268029)
30. Rozmiarek H. 1999. Convulsions in rodents related to frequent handling. Lab Anim Sci 49:468-469. (Pubitemid 29508433)
31. Schoemaker H, Hicks PE, Langer SZ. 1987. Calcium channel receptor binding studies for diltiazem and its major metabolites: functional correlation to inhibition of portal vein myogenic activity. J Cardiovasc Pharmacol 9:173-180. (Pubitemid 17234498)
32. Shearman LP, Stribling DS, Camacho RE, Rosko KM, Wang J, Tong S, Feng Y, Marsh DJ, Yu H, Guan X, et al. 2008. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents. Eur J Pharmacol 579:215-224.
33. Thakur GA, Nikas SP, Makriyannis A. 2005. CB1 cannabinoid receptor ligands. Mini Rev Med Chem 5:631-640.
34. Trojniar W, Wise RA. 1991. Facilitory effect of delta9- tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology 103:172-176.
35. Walker ML, Schwartz SM, Wilson ME, Musey PI. 1984. Estimation of body fat in female rhesus monkeys. Am J Physiol Anthropol 63:323-329. (Pubitemid 14142309)
36. Wallmichrath I, Szabo B. 2002. Analysis of the effect of cannabinoids on GABAergic neurotransmission in the substantia nigra pars reticulata. Naunyn-Schmiedebergs Arch Pharmacol 365:326-334. (Pubitemid 34280373)
37. Wang J, Della Penna K, Wang H, Karczewski J, Connolly TM, Koblan KS, Bennett PB, Salata JJ. 2003. Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol Heart Circ Physiol 284:H256-H267. (Pubitemid 36076293)
38. Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. 2005. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci 26:609-617. (Pubitemid 41636305)